E-ISSN 2534-9821
 
2023, Vol: 7, Issue: 12
7 / 12Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Copyright Transfer Form

Original Article
Online Published: 13 May 2018
 


EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY

Eman Arif Rahman, Sri Vitayani Muchtar, Farida Tabri, Siswanto Wahab, Anni Adriani, Arifin Seweng, Rizalinda Sjahril.


Abstract
Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae. In leprosy, cell-mediated immune responses are an important aspect of host resistance to mycobacterial infections and allegedly governed by anequilibrium between type 1 cytokines including Interleukin-12 (IL-12); with type 2 cytokines such as Interleukin-4 (IL-4). Currently, the World Health Organization (WHO) recommends 3 leprosy treatment regimens, one of them is Rifampicin Ofloxacin Minocycline (ROM). To date, studies on the effects of ROM on leprosy have been limited, none have specifically assessed the effects of ROM on specific immune systems, especially cytokines.
Methods: The study was conducted by prospective research method. The sample of this research were all multibacillary (MB) type of leprosy patients according to WHO classification who had received ROM therapy and recorded as the patient at research location and had medical record previous of interleukin-12 and interleukin-4 levels. After 12 months of ROM therapy, blood samples were collected and calculated using the Enzyme-Linked Immunosorbent Assay (ELISA) using the Quantikine® high sensitivity (HSv) kit.
Results: There was a statistically significant increase in IL-4 after 12 months of a 3-months-ROM therapy. In contrast, the levels of IL-12 after 12 months showed significant decreases.
Conclusions: Increased levels of IL-4 and decreased IL-12 can be caused by many factors. Therefore, further research with a closer supervision is required.

Key words: Leprosy, Rifampicin Ofloxacin Minocycline therapy, Interleukin-12, Interleukin-4


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Eman Arif Rahman
Articles by Sri Vitayani Muchtar
Articles by Farida Tabri
Articles by Siswanto Wahab
Articles by Anni Adriani
Articles by Arifin Seweng
Articles by Rizalinda Sjahril
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Rahman EA, Muchtar SV, Tabri F, Wahab S, Adriani A, Seweng A, Sjahril R. EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY. Int J Med Rev Case Rep. 2018; 2(4): 161-165. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS

Web Style

Rahman EA, Muchtar SV, Tabri F, Wahab S, Adriani A, Seweng A, Sjahril R. EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY. https://www.mdpub.net/?mno=297715 [Access: April 02, 2025]. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS

AMA (American Medical Association) Style

Rahman EA, Muchtar SV, Tabri F, Wahab S, Adriani A, Seweng A, Sjahril R. EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY. Int J Med Rev Case Rep. 2018; 2(4): 161-165. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS


Vancouver/ICMJE Style

Rahman EA, Muchtar SV, Tabri F, Wahab S, Adriani A, Seweng A, Sjahril R. EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY. Int J Med Rev Case Rep. (2018), [cited April 02, 2025]; 2(4): 161-165. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS


Harvard Style

Rahman, E. A., Muchtar, . S. V., Tabri, . F., Wahab, . S., Adriani, . A., Seweng, . A. & Sjahril, . R. (2018) EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY. Int J Med Rev Case Rep, 2 (4), 161-165. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS


Turabian Style

Rahman, Eman Arif, Sri Vitayani Muchtar, Farida Tabri, Siswanto Wahab, Anni Adriani, Arifin Seweng, and Rizalinda Sjahril. 2018. EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY. International Journal of Medical Reviews and Case Reports, 2 (4), 161-165. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS


Chicago Style

Rahman, Eman Arif, Sri Vitayani Muchtar, Farida Tabri, Siswanto Wahab, Anni Adriani, Arifin Seweng, and Rizalinda Sjahril. "EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY." International Journal of Medical Reviews and Case Reports 2 (2018), 161-165. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS


MLA (The Modern Language Association) Style

Rahman, Eman Arif, Sri Vitayani Muchtar, Farida Tabri, Siswanto Wahab, Anni Adriani, Arifin Seweng, and Rizalinda Sjahril. "EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY." International Journal of Medical Reviews and Case Reports 2.4 (2018), 161-165. Print. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS


APA (American Psychological Association) Style

Rahman, E. A., Muchtar, . S. V., Tabri, . F., Wahab, . S., Adriani, . A., Seweng, . A. & Sjahril, . R. (2018) EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY. International Journal of Medical Reviews and Case Reports, 2 (4), 161-165. doi:10.5455/IJMRCR.MULTIBACILLARY-TYPE-LEPROSY-INTERLEUKINS


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports  (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31,  Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500